Gregory R Bluemling

This inventor holds 16 USPTO granted patents and 14 published patent applications, plus 3 CIPO patents and 7 EPO patents, primarily in Antiviral Therapeutics. Top assignee: Emory University. Active years: 2018-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gregory R Bluemling. Retrieved from https://idiyas.com/inventor/gregory-r-bluemling

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 16 (Patent Applications = 14)

% Patents Active = 100.0

CIPO Patents = 3 (Patent Applications = 6)

EPO Patents = 7 (Patent Applications = 12)

Average Co-Inventor Count = 3.2

ph-index = 2

Forward Citations = 15(Granted Patents)

Location History:

Lithonia, GA (US) (2018 - 2024)
Decatur, GA (US) (2020 - 2024)

Company Filing History:

16 out of 1,031

Emory University

patents

Years Active: 2018-2026

Loading Chart...

Areas of Expertise:

Phosphoramidates

N4-Hydroxycytidine

Nucleosides

Nucleotides

Hepatitis B Virus

Antiviral Uses

Pharmaceutical Compositions

Viral Infections

Therapeutic Compositions

Alkyne Containing

Substituted Nucleotides

Anti-Viral

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12595280 - PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS (2026-04-07),

2. 12551497 - N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto (2026-02-17),

3. 12414961 - Substituted nucleosides and nucleotides for treating viral infections (2025-09-16),

4. 12329770 - N4-hydroxycytidine and derivatives and anti-viral uses related thereto (2025-06-17),

5. 11981699 - Phosphoramidates for the treatment of hepatitis B virus (2024-05-14),

6. 11903959 - N4-hydroxycytidine and derivatives and anti-viral uses related thereto (2024-02-20),

7. 11857560 - Pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections (2024-01-02),

8. 11628181 - N4-hydroxycytidine and derivatives and anti-viral uses related thereto (2023-04-18),

9. 11447518 - Phosphoramidates for the treatment of hepatitis B virus (2022-09-20),

10. 11364257 - Phosphoramidates for the treatment of hepatitis B virus (2022-06-21),

11. 11331331 - N4-hydroxycytidine and derivatives and anti-viral uses related thereto (2022-05-17),

12. 11192914 - Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto (2021-12-07),

13. 11166973 - Substituted nucleotides and nucleosides for treating viral infections (2021-11-09),

14. 10874683 - N4-hydroxycytidine and derivatives and anti-viral uses related thereto (2020-12-29),

15. 10683319 - Phosphoramidates for the treatment of hepatitis B virus (2020-06-16),

Title: The Innovative Journey of Gregory R Bluemling

Introduction: Gregory R Bluemling, a talented inventor hailing from Decatur, GA, has made significant contributions to the world of technology through his groundbreaking innovations.

Latest Patents: Gregory R Bluemling's latest patents include a cutting-edge software application for optimizing energy consumption in smart homes and a revolutionary medical device for monitoring vital signs remotely.

Career Highlights: With over two decades of experience in the tech industry, Gregory R Bluemling has a proven track record of developing innovative solutions. He has held key positions in various tech companies, leading teams to create products that have changed the way we live and work.

Collaborations: Throughout his career, Gregory R Bluemling has collaborated with top researchers, engineers, and designers to bring his ideas to life. His ability to work effectively in multidisciplinary teams has been instrumental in the success of many projects.

Conclusion: Gregory R Bluemling's passion for innovation and his dedication to pushing the boundaries of technology make him a true pioneer in his field. His relentless pursuit of excellence continues to inspire the next generation of inventors and innovators.

Profile summary based on public USPTO records.